sars-cov spike/s1 protein (Sino Biological)
Sino Biological is a verified supplier 
Sino Biological manufactures this product 
95
Structured Review
Sino Biological
sars-cov spike/s1 protein
Sars Cov Spike/S1 Protein, supplied by Sino Biological, used in various techniques. Bioz Stars score: 95/100, based on 233 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/s1+proteins/SARS-CoV+Spike%2FS1+Protein/custom%4040150-v05h1%4042206642
Average 95 stars, based on 233 article reviews
Sars Cov Spike/S1 Protein, supplied by Sino Biological, used in various techniques. Bioz Stars score: 95/100, based on 233 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/s1+proteins/SARS-CoV+Spike%2FS1+Protein/custom%4040150-v05h1%4042206642
Average 95 stars, based on 233 article reviews
sars-cov spike/s1 protein - by Bioz Stars,
2026-10
95/100 stars
Images
Related Articles
Concentration Assay:Article Title: Engineered bispecific antibodies with enhanced breadth and potency against SARS-CoV-2 variants and SARS-related coronaviruses. Article Snippet: 1 Institute of Human Virology, Department of Pathogen Biology and Biosecurity, Key Laboratory of Tropical Disease Control of Ministry of Education, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China 2 College of Basic Medical Sciences, Hengyang Medical School, University of South China & MOE Key Lab of Rare Pediatric Diseases, Hengyang, China 3 Translational Medicine Institute, Hengyang Medical School, The First People’s Hospital of Chenzhou, University of South China, Chenzhou, China 4 Department of Microbiology, Faculty of Naval Medicine, Naval Medical University, Shanghai, China 5 Department of Microbiology and Immunology, University of Otago, Dunedin, New Zealand Abstract The concern of COVID-19 persists due to the continuous emergence of variants and the potential spillover of animal coronaviruses.. The broad-spectrum neutralizing antibodies play a pivotal role in the prevention and treatment of coronavirus (CoV) infections.. Here, we constructed 18 bi-specific antibodies (bsAbs) using 9 antibodies isolated from COVID-19 convalescents and vaccinated individuals, designed as dual variable domain immunoglobulin (DVD-Ig). Article Title: A new vaccine strategy based on VLSs for use against SARS-CoV-2 variants: Evaluation of their immune effectiveness and investigation of the mechanism Article Snippet: The S1 antigen was621 quantified usedtheSARS-CoV-2 Spike Protein ELISA Kit (ACRO, Cat# RAS-A039,622 Beijing, China) and the Nucleoprotein was quantified used the SARS-CoV-2623 (2019-nCoV) Nucleoprotein ELISA Kit (Jiya Biotechnology, Shanghai, China).624 S1-RBD IgG assays were used SARS-CoV-2 RBD (Wild type) antibody (IgG)625 Detection Kits (Enzyme-linked Immunosorbent Assay) (Vazyme, Cat# DD3201-01,626 China) and SARS-CoV-2 RBD (Omicron BA.4/5) antibody (IgG) Detection Kits627 (Enzyme-linked Immunosorbent Assay) (Vazyme, Cat# DD3214-01, China).628 S1 antibody was detected by ELISA. .. Recombinant:Article Title: Antibody Response Following the Intranasal Administration of SARS-CoV-2 Spike Protein-CpG Oligonucleotide Vaccine Article Snippet: .. The RBD and Article Title: Key β1-4 galactosylated glycan receptors of SARS-CoV-2 and its inhibitor from the galactosylated glycoproteins of bovine milk. Article Snippet: .. Initially, High Performance Liquid Chromatography:Article Title: Antibody Response Following the Intranasal Administration of SARS-CoV-2 Spike Protein-CpG Oligonucleotide Vaccine Article Snippet: .. The RBD and Enzyme-linked Immunosorbent Assay:Article Title: A new vaccine strategy based on VLSs for use against SARS-CoV-2 variants: Evaluation of their immune effectiveness and investigation of the mechanism Article Snippet: The S1 antigen was621 quantified usedtheSARS-CoV-2 Spike Protein ELISA Kit (ACRO, Cat# RAS-A039,622 Beijing, China) and the Nucleoprotein was quantified used the SARS-CoV-2623 (2019-nCoV) Nucleoprotein ELISA Kit (Jiya Biotechnology, Shanghai, China).624 S1-RBD IgG assays were used SARS-CoV-2 RBD (Wild type) antibody (IgG)625 Detection Kits (Enzyme-linked Immunosorbent Assay) (Vazyme, Cat# DD3201-01,626 China) and SARS-CoV-2 RBD (Omicron BA.4/5) antibody (IgG) Detection Kits627 (Enzyme-linked Immunosorbent Assay) (Vazyme, Cat# DD3214-01, China).628 S1 antibody was detected by ELISA. .. Incubation:Article Title: A new vaccine strategy based on VLSs for use against SARS-CoV-2 variants: Evaluation of their immune effectiveness and investigation of the mechanism Article Snippet: The S1 antigen was621 quantified usedtheSARS-CoV-2 Spike Protein ELISA Kit (ACRO, Cat# RAS-A039,622 Beijing, China) and the Nucleoprotein was quantified used the SARS-CoV-2623 (2019-nCoV) Nucleoprotein ELISA Kit (Jiya Biotechnology, Shanghai, China).624 S1-RBD IgG assays were used SARS-CoV-2 RBD (Wild type) antibody (IgG)625 Detection Kits (Enzyme-linked Immunosorbent Assay) (Vazyme, Cat# DD3201-01,626 China) and SARS-CoV-2 RBD (Omicron BA.4/5) antibody (IgG) Detection Kits627 (Enzyme-linked Immunosorbent Assay) (Vazyme, Cat# DD3214-01, China).628 S1 antibody was detected by ELISA. .. |